Key studies relating baseline SUVmax with outcome in FL
| Reference . | Patients, n . | Median baseline SUVmax (range) . | HT . | PFS . |
|---|---|---|---|---|
| PET in PRIMA (retrospective)41 | 58 | 11.7 (4.6-35.6) | No patients with HT | No association of bSUVmax with PFS (P = 0.53). ROC analysis did not identify an optimal pretreatment SUVmax cutoff with a significant impact on PFS |
| FOLLCOLL (retrospective)28 | 181 | 10 (3-35; IQR 7-14). No correlation with histologic grade, P = 0.66. Best cutoff on ROC and X-tile analysis SUVmax 9.4 | 2 patients with HT | SUVmax > 9.4: 5-y PFS 62%, median PFS 78.7 mo. SUVmax <9.4: 5-y PFS 47%, median PFS 48.7 mo. P = 0.0318. No difference in OS, 93.7% vs 88.4%; P = .15 |
| GALLIUM (prospective)31 | 549 | Range, 3-64; median, 12.4 (8.1-28.0) in HT; median 11.8 (3.1-64.4) in non-HT | 15 patients (2.7%) with HT at 5 y | No association of bSUVmax with PFS, Q1 vs Q4; HR, 1.14 (95% CI, 0.72-1.81), P = 0.58 |
| Strati et al (retrospective)25 | 346 | 11 (1.5-42) 52 patients (15%) with SUVmax >18 | HT excluded from study population | No effect on PFS if treated with R-CHOP or other CIT. Inferior 8-y OS if SUVmax >18 (65% vs. 89%; P = 0.001) |
| Reference . | Patients, n . | Median baseline SUVmax (range) . | HT . | PFS . |
|---|---|---|---|---|
| PET in PRIMA (retrospective)41 | 58 | 11.7 (4.6-35.6) | No patients with HT | No association of bSUVmax with PFS (P = 0.53). ROC analysis did not identify an optimal pretreatment SUVmax cutoff with a significant impact on PFS |
| FOLLCOLL (retrospective)28 | 181 | 10 (3-35; IQR 7-14). No correlation with histologic grade, P = 0.66. Best cutoff on ROC and X-tile analysis SUVmax 9.4 | 2 patients with HT | SUVmax > 9.4: 5-y PFS 62%, median PFS 78.7 mo. SUVmax <9.4: 5-y PFS 47%, median PFS 48.7 mo. P = 0.0318. No difference in OS, 93.7% vs 88.4%; P = .15 |
| GALLIUM (prospective)31 | 549 | Range, 3-64; median, 12.4 (8.1-28.0) in HT; median 11.8 (3.1-64.4) in non-HT | 15 patients (2.7%) with HT at 5 y | No association of bSUVmax with PFS, Q1 vs Q4; HR, 1.14 (95% CI, 0.72-1.81), P = 0.58 |
| Strati et al (retrospective)25 | 346 | 11 (1.5-42) 52 patients (15%) with SUVmax >18 | HT excluded from study population | No effect on PFS if treated with R-CHOP or other CIT. Inferior 8-y OS if SUVmax >18 (65% vs. 89%; P = 0.001) |
IQR, interquartile range; ROC, receiver operating characteristic.